| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout","as_of":"2026-04-06T22:34:24.548125+00:00","canonical_url":"https://www.fool.com/coverage/stock-market-today/2026/04/06/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout-agreement/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout","article_chars":4352,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_ded57e1eabab7431","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/stock-market-today/2026/04/06/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout-agreement/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-07T17:01:09.602843+00:00","extraction_method":"heuristic","fetched_description":"Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock\u2019s move reflects Neurocrine Biosciences\u2019 (NASDAQ:NBIX) $53-per-share all-cash acquisition offer for Soleno. Investors are watching for any deal-related regulatory or clo","fetched_title":"Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement | Nasdaq","final_url":"https://www.nasdaq.com/articles/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout","source_event_id":"evt_ff0785ba9ca5","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"f819d9ab56875460","kind":"unusual_volume","published_at":"2026-04-06T21:40:08+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.95,"dates_mentioned":["April 6, 2026"],"entities":[{"asset_class":"equity","name":"Soleno Therapeutics","relevance":"high","symbol":"SLNO","type":"company"},{"asset_class":"equity","name":"Neurocrine Biosciences","relevance":"high","symbol":"NBIX","type":"company"}],"event_type":"merger_acquisition","information_gaps":["Exact baseline volume for comparison is not provided."],"key_facts":["Soleno Therapeutics closed at $52.26, up 32.31%.","Neurocrine Biosciences offered $53 per share for Soleno.","Trading volume reached 58 million shares, 2,148% above the average of 2.6 million shares."],"numeric_claims":[{"label":"trading volume increase","value":"2,148%"},{"label":"acquisition offer","value":"$2.9 billion"}],"primary_claim":"Soleno Therapeutics' trading volume surged 2,148% above its three-month average due to a buyout offer.","relevance_score":0.9,"sentiment":"positive","source_quality":"high","summary":"Soleno Therapeutics (NASDAQ:SLNO) experienced a significant increase in trading volume, reaching 58 million shares, which is 2,148% above its three-month average, following a $2.9 billion acquisition offer from Neurocrine Biosciences (NASDAQ:NBIX).","topics":["merger","acquisition","trading volume","biotechnology"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock\u2019s move reflects Neurocrine Biosciences\u2019 (NASDAQ:NBIX) $53-per-share all-cash acquisition offer for Soleno. Investors are watching for any deal-related regulatory or clo","tickers":[],"title":"Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement","url":"https://www.fool.com/coverage/stock-market-today/2026/04/06/stock-market-today-april-6-soleno-therapeutics-climbs-after-29-billion-all-cash-buyout-agreement/"}... |